. (2023). Combinations of medicines in patients with polypharmacy aged 65-100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions. Plos One, 18, e0281466. http://doi.org/10.1371/journal.pone.0281466
T. van Staa
First name
T.
Middle name
P.
Last name
van Staa
. (2022). Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Osteoporos Int. http://doi.org/10.1007/s00198-021-06262-1
. (2022). Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc21-1113
. (1998). Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol.
. (1998). Postmarketing surveillance of the safety of cyclic etidronate. Pharmacotherapy.
. (2000). Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford).
. (2000). The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/1099-1557(200009/10)9:5<359::aid-pds507>3.0.co;2-e
. (2000). Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone.
. (2000). Use of oral corticosteroids and risk of fractures. J Bone Miner Res. http://doi.org/10.1359/jbmr.2000.15.6.993
. (2000). Use of oral corticosteroids in the United Kingdom. Qjm.